Millions of people worldwide suffer from neurodegenerative diseases that impair memory, focus and thinking and impact their ability to go about their daily lives. By applying our novel approach, we believe the synaptic dysfunction responsible for disease symptoms and progression can be reversed before the death of nerve cells.
Our Approach
HOPE THROUGH SCIENCE
We are developing neflamapimod – an investigational, orally administered, small molecule brain penetrant that inhibits the protein kinase p38 alpha. Extensive research has shown that p38 alpha is a key driver of synaptic dysfunction, the reversible aspect of the neurodegenerative process. The preclinical and clinical data with neflamapimod, including our ongoing Phase 2 RewinD-LB trial in patients with dementia with Lewy bodies (DLB), suggest that inhibition of p38 alpha by neflamapimod reverses the synaptic dysfunction that underlies development of symptoms and disease progression in the early stages of many neurological disorders.
PipelinePlacebo-controlled results of RewinD-LB clinical trial published in Alzheimer’s Research & Therapy provides further evidence of the potential of neflamapimod to slow clinical disease progression in DLB Translational research findings
On average, reduction in plasma neurofilament light levels was observed during the first 12 weeks of treatment, with a greater decline in participants with baseline levels at or above the
New 50 mg tablet formulation delivers an improved pharmacokinetic profile and enables greater exposure and patient convenience FDA removal of the prior drug exposure limit provides greater dosing flexibility in
